Irrespective of these nuances, tMN typically exhibit poorer outcomes likely as a result of complex genomic architecture, including complex karyotypes, del(5q)/5-, del(7q)/7-, and TP53 mutations [5–8]. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.